1
|
Paronis CA, Chopda GR, Vemuri K, Zakarian AS, Makriyannis A, Bergman J. Long-Lasting In Vivo Effects of the Cannabinoid CB1 Antagonist AM6538. J Pharmacol Exp Ther 2018; 364:485-493. [PMID: 29311110 DOI: 10.1124/jpet.117.245647] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2017] [Accepted: 01/04/2018] [Indexed: 11/22/2022] Open
Abstract
AM6538 is a cannabinoid antagonist that binds CB1 receptors expressed in HEK-293 cells in a wash-resistant manner. The effects of AM6538 in live animals has not previously been established. We characterized the antagonist effects of AM6538 in male mice, using a warm-water tail-withdrawal assay, and in male squirrel monkeys trained to discriminate the CB1 agonist AM4054 from vehicle. The cannabinoid agonists WIN 55,212, Δ9-tetrahydrocannabinol (THC), and AM4054 all produced 100% maximum possible antinociceptive effects in mice following vehicle pretreatment. One-hour pretreatment with increasing doses of AM6538 (0.1-10 mg/kg) produced first rightward, then downward shifts of the agonist dose-effect functions. Rimonabant, 1-10 mg/kg, produced parallel rightward shifts of the AM4054 dose-effect functions, and baseline effects of AM4054 were nearly recovered within 24 hours following 10 mg/kg of rimonabant. In contrast, in mice treated with 10 mg/kg of AM6538, antagonism of THC or AM4054 lasted up to 7 days. AM6538 also antagonized the discriminative stimulus effects of AM4054 in squirrel monkeys in a dose-related manner, and the effects of 3.2 mg/kg of AM6538 endured for more than 7 days. The effective reduction in CB1 receptor reserve was used to calculate the relative efficacy (tau values) of WIN 55,212, THC, and AM4054 in mice and of AM4054 monkeys, with results indicating that THC has a lower efficacy than WIN 55,212 or AM4054 in mice. These results demonstrate that AM6538 is a long-acting CB antagonist in vivo, and further suggest that differences in CB efficacy can be revealed in behavioral assays following AM6538 treatment.
Collapse
Affiliation(s)
- Carol A Paronis
- Center for Drug Discovery (C.A.P., K.V., A.M.) and Department of Pharmaceutical Sciences (C.A.P., G.R.C., A.M.), Northeastern University, Boston, Massachusetts; and Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P., A.S.Z., J.B.)
| | - Girish R Chopda
- Center for Drug Discovery (C.A.P., K.V., A.M.) and Department of Pharmaceutical Sciences (C.A.P., G.R.C., A.M.), Northeastern University, Boston, Massachusetts; and Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P., A.S.Z., J.B.)
| | - Kiran Vemuri
- Center for Drug Discovery (C.A.P., K.V., A.M.) and Department of Pharmaceutical Sciences (C.A.P., G.R.C., A.M.), Northeastern University, Boston, Massachusetts; and Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P., A.S.Z., J.B.)
| | - Ani S Zakarian
- Center for Drug Discovery (C.A.P., K.V., A.M.) and Department of Pharmaceutical Sciences (C.A.P., G.R.C., A.M.), Northeastern University, Boston, Massachusetts; and Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P., A.S.Z., J.B.)
| | - Alexandros Makriyannis
- Center for Drug Discovery (C.A.P., K.V., A.M.) and Department of Pharmaceutical Sciences (C.A.P., G.R.C., A.M.), Northeastern University, Boston, Massachusetts; and Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P., A.S.Z., J.B.)
| | - Jack Bergman
- Center for Drug Discovery (C.A.P., K.V., A.M.) and Department of Pharmaceutical Sciences (C.A.P., G.R.C., A.M.), Northeastern University, Boston, Massachusetts; and Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P., A.S.Z., J.B.)
| |
Collapse
|
3
|
Kangas BD, Bergman J. A novel touch-sensitive apparatus for behavioral studies in unrestrained squirrel monkeys. J Neurosci Methods 2012; 209:331-6. [PMID: 22790109 DOI: 10.1016/j.jneumeth.2012.06.028] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2012] [Revised: 06/14/2012] [Accepted: 06/25/2012] [Indexed: 10/28/2022]
Abstract
Despite the increasing sophistication and affordability of touch-sensitive technology, its use in the behavioral sciences has been limited. The present paper describes the design and empirical validation of a novel touch-sensitive operant conditioning chamber for use with unrestrained squirrel monkeys. In addition, results from a variant of a commonly employed animal model of learning, the repeated acquisition task, demonstrate the effectiveness of this chamber in programming an assay of complex behavior. Finally, results from a study with Δ(9)-tetrahydrocannabinol, the active ingredient in marijuana, show that its effects in this novel touchscreen chamber were consistent with its dose-related effects on learning using more conventional approaches. Overall, these studies indicate the touchscreen apparatus provides effective means for programming complex behavioral tasks to assess the effects of pharmacological agents on cognitive function.
Collapse
Affiliation(s)
- Brian D Kangas
- Preclinical Pharmacology Laboratory, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA.
| | | |
Collapse
|